The primary focus of the AuCoin laboratory is to develop diagnostics and therapeutics for infectious diseases. Current funding includes three research grants through the National Institutes of Health. Two additional grants were recently secured through the Department of Homeland Security (DHS) and the Naval Research Laboratory (DoD). All these projects rely on the identification of secreted or circulating microbial antigens that can be targeted for diagnosis of disease. The AuCoin laboratory has developed a novel platform technology termed “In vivo Microbial Antigen Discovery” or InMAD to identify such secreted antigens. InMAD is currently being utilized to identify candidate diagnostic antigens secreted during infection with Burkholderia pseudomallei (melioidosis), Aspergillus fumigatus (invasive aspergillosis) and Francisella tularensis (tularemia).